ClinicalTrials.gg
RecruitingNCT06169150Updated Aug 5, 2026

Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

An observational study in Nervous System Disease and Immune System Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 2 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
2 Years to 120 Years
Sex
All
01

Study summary

Background:

Immune system and nervous system have significant interaction so that People with immunity diseases can have complications that affect the nervous system and people with some neurological disease may have defects in their immune system.These complications can affect many body functions, including how they move, walk, think, and feel. Researchers do not fully understand how immune diseases affect the nervous system. By learning more, they hope to create more effective treatments.

Objective:

To learn more about the interaction between immune and nervous system and how immunity disease affect the nervous system.

Eligibility:

People aged 2 years and older with an immunity disease. Their healthy biological relatives and other healthy volunteers are also needed.

Design:

Participants will be screened. Blood will be drawn for research. They may have imaging scans. Adults may undergo lumbar puncture: A needle will be inserted into their back to collect fluid from the space around the spinal cord. The imaging scans and lumbar puncture will be optional for healthy relatives and volunteers.

All participants will have 1 study visit per year for 5 years.

They will be asked to donate samples of body fluids at each visit. Blood samples are required for the study. All other donations are optional. These may include saliva, urine, breast milk, stool, vaginal secretions, and wound drainage.

Affected participants may be asked for a skin biopsy: A small sample of skin will be removed. They may also be photographed or videotaped to record the symptoms of their disease.

Tests for each study visit may be spread over several days, if needed.

Visits may be at the clinic. Participants may also collect their own samples at home and send them to the researchers....

Read the detailed description

Study Description:

In this study, we will characterize clinical neurologic presentations of patients with known or unevaluated primary and acquired errors of immunity. Investigating the underlying mechanisms of neurologic diseases and their genetic and immunologic bases requires periodic clinical evaluation of these patients and research analyses of their biospecimens. These biospecimens include blood, cerebrospinal fluid (CSF), urine, saliva, skin, breast milk, stool, vaginal specimens, and wound drainage. Magnetic resonance imaging (MRI) of the neural axis may also be done. Data and excess biospecimens from routine clinical care may also be collected and used for research. We propose to evaluate patients who either have or are suspected of having immune defects or other types of host defense defects with neurologic presentations. Unaffected biological relatives and healthy volunteers will also be enrolled as controls for research analyses.

Primary Objectives:

  1. Clinically characterize neurologic manifestations of errors of immunity via neurologic exam and neuroimaging.
  2. Determine genetic defects in participants.

Secondary Objective:

Characterize immune cells in CSF and blood.

Primary Endpoints:

  1. Clinical characterization of neurologic manifestations in participants with recognized and unrecognized errors of immunity based on neurologic examination, neuroimaging, and other necessary neurologic tests depending on clinical presentation.
  2. Characterization of inherited or acquired errors of immunity in participants with rare neurologic diseases.

Secondary Endpoint:

Characterization and comparison of immunologic phenotypes of both CSF and blood in participants with errors of immunity vs healthy controls, and longitudinally in participants using cellular and molecular immunologic techniques, including but not limited to immune cell phenotype, transcriptomics, metagenomics, and immune biomarkers.

02

Conditions studied

  • Nervous System Disease
  • Immune System Disease

Keywords

  • Errors Of Immunity
  • Neurological Diseases
  • Neuroinflammation
  • Neuroinfections
  • Neurodegeneration
  • Primary Immunodeficiency
  • Neuropathogenesis
  • Inborn Errors of Immunity
03

In context

Nervous System Diseases

759 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's planned enrollment of 350 is above the median of 150 across 229 observational studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.

Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from NIH protocols 15-N-0125 (Natural History Study of Inflammatory and Infectious Diseases of the Nervous System) and 93-I-0119 (Detection and Characterization of Host Defense Defects), or from referrals. Biological relatives of affected participants may be enrolled on this study as controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Aged >=2 years. To be seen at the NIH CC, participants must be >=3 years of age.
  2. Willing to allow specimens and data to be stored for future research.
  3. Willing to allow genetic testing on their biospecimens.
  4. Able to provide (for ages >=18 years) or has parent(s) or guardian(s) who can provide permission to participate on their behalf (for ages \<18 years).

    • Decisionally impaired affected adult participants may have a legally authorized representative (LAR) to provide informed consent on their behalf.

Additional Inclusion Criterion for Affected Participants:

Has a primary or acquired immunodeficiency and known or suspected infection or inflammation of the nervous system or post-infection sequelae, based on clinical or imaging data provided by the referral facility, or is at risk of developing such a neurologic complication. For the purpose of this study, neuroinfectious disease or neuroinflammation is defined as any of the following:

  1. Any neurologic symptoms accompanied by CSF with evidence of inflammation (which may include pleocytosis, hypoglycorrachia, elevated protein, or other evidence of intrathecal immune activation, including immunoglobulin [Ig] G index or presence of oligoclonal bands).
  2. Systemic infection or inflammatory disease with neurologic involvement.
  3. Neuroimaging suggestive of infection or inflammation (for example, presence of contrast-enhancing lesions on CT or MRI).
  4. Clinical presentation suggestive of infection or inflammatory process of the nervous system without better explanation.
  5. History of infection or inflammatory process of the nervous system.

Affected participants must also have their own primary health care provider to manage their condition outside the NIH.

Additional Inclusion Criteria for Biological Relatives and Healthy Volunteers:

  1. Is either a biological relative of an affected participant or is unrelated.
  2. Does not have a known diagnosis of neuroinfectious disease or neuroinflammation.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Pregnant (for biological relatives and healthy volunteers).
  2. Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)

Groups and cohorts

  • Healthy Controls

    Biological relatives or unrelated persons without a known diagnosis of neuroinfectious disease or neuroinflammation.

  • Primary or acquired immunodeficiency

    Known or suspected infection or inflammation of the nervous system or post infection sequelae, or is at risk of developing such a neurologic complication.

06

What researchers measure

Primary outcomes

  1. Clinical characterization of neurologic manifestations in participants with recognized and unrecognized errors of immunity based on neurologic examination, neuroimaging, and other necessary neurologic tests depending on clinical presentation.

    Clinically characterize neurologic manifestations of errors of immunity via neurologic exam and neuroimaging.

    Time frame: Through end of participation.

  2. Characterization of inherited or acquired errors of immunity in participants with rare neurologic diseases.

    Determine genetic defects in participants.

    Time frame: Through end of participation.

Secondary outcomes

  1. Characterization and comparison of immunologic phenotypes of both CSF and blood in participants with errors of immunity vs healthy controls, and longitudinally in participants using cellular and molecular immunologic techniques.

    Characterize immune cells in CSF and blood.

    Time frame: Through end of participation.

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Raw and processed de-identified data from the whole blood bulk RNA-seq and single-cell CITE-seq will be available from the NCBI Gene Expression Omnibus.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be shared into GEO following publication of manuscripts.

Access criteria: GEO is an open-access database.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2043, 227 months after the start.

Of 97 non-industry observational studies under Nervous System Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 150. This study's planned 227 months is above that.

Counting every sponsor, half of 114 studies reached it within 53 months; a quarter within 20 and three quarters within 121.

Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Dec 13, 2023
StartActual
Jan 12, 2024
Primary completionEst.
Jan 1, 2043
CompletionEst.
Oct 1, 2043
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06169150
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Jan 12, 2024
Primary completion
Jan 1, 2043 (estimated)
Completion
Oct 1, 2043 (estimated)
Last update
Aug 5, 2026

Study contacts

Kelsey L Yoo, P.A.-C
Contact
kelsey.yoo@nih.gov
(240) 656-0596
Farinaz Safavi, M.D.
Contact
farinaz.safavi@nih.gov
(301) 496-4952
Farinaz Safavi, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion